156 related articles for article (PubMed ID: 28350009)
1. Activation of ERK1/2 Causes Pazopanib Resistance via Downregulation of DUSP6 in Synovial Sarcoma Cells.
Yokoyama N; Matsunobu T; Matsumoto Y; Fukushi JI; Endo M; Hatano M; Nabeshima A; Fukushima S; Okada S; Iwamoto Y
Sci Rep; 2017 Mar; 7():45332. PubMed ID: 28350009
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma.
Yamada S; Imura Y; Nakai T; Nakai S; Yasuda N; Kaneko K; Outani H; Takenaka S; Hamada K; Myoui A; Araki N; Ueda T; Itoh K; Yoshikawa H; Naka N
BMC Cancer; 2017 May; 17(1):334. PubMed ID: 28511645
[TBL] [Abstract][Full Text] [Related]
3. The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo.
Booth L; Roberts JL; Sander C; Lee J; Kirkwood JM; Poklepovic A; Dent P
Oncotarget; 2017 Mar; 8(10):16367-16386. PubMed ID: 28146421
[TBL] [Abstract][Full Text] [Related]
4. Differential expression profiles and roles of inducible DUSPs and ERK1/2-specific constitutive DUSP6 and DUSP7 in microglia.
Ham JE; Oh EK; Kim DH; Choi SH
Biochem Biophys Res Commun; 2015 Nov; 467(2):254-60. PubMed ID: 26435497
[TBL] [Abstract][Full Text] [Related]
5. Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy.
Ishibe T; Nakayama T; Okamoto T; Aoyama T; Nishijo K; Shibata KR; Shima Y; Nagayama S; Katagiri T; Nakamura Y; Nakamura T; Toguchida J
Clin Cancer Res; 2005 Apr; 11(7):2702-12. PubMed ID: 15814652
[TBL] [Abstract][Full Text] [Related]
6. Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes.
Fleuren EDG; Vlenterie M; van der Graaf WTA; Hillebrandt-Roeffen MHS; Blackburn J; Ma X; Chan H; Magias MC; van Erp A; van Houdt L; Cebeci SAS; van de Ven A; Flucke UE; Heyer EE; Thomas DM; Lord CJ; Marini KD; Vaghjiani V; Mercer TR; Cain JE; Wu J; Versleijen-Jonkers YMH; Daly RJ
Cancer Res; 2017 Aug; 77(16):4279-4292. PubMed ID: 28634201
[TBL] [Abstract][Full Text] [Related]
7. A novel multi-kinase inhibitor pazopanib suppresses growth of synovial sarcoma cells through inhibition of the PI3K-AKT pathway.
Hosaka S; Horiuchi K; Yoda M; Nakayama R; Tohmonda T; Susa M; Nakamura M; Chiba K; Toyama Y; Morioka H
J Orthop Res; 2012 Sep; 30(9):1493-8. PubMed ID: 22359392
[TBL] [Abstract][Full Text] [Related]
8. Pazopanib regresses a doxorubicin-resistant synovial sarcoma in a patient-derived orthotopic xenograft mouse model.
Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Miyake M; Nelson SD; Russell TA; Dry SM; Li Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Higuchi T; Singh SR; Tsuchiya H; Hoffman RM
Tissue Cell; 2019 Jun; 58():107-111. PubMed ID: 31133237
[TBL] [Abstract][Full Text] [Related]
9. Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation.
Grasso S; Tristante E; Saceda M; Carbonell P; Mayor-López L; Carballo-Santana M; Carrasco-García E; Rocamora-Reverte L; García-Morales P; Carballo F; Ferragut JA; Martínez-Lacaci I
Neoplasia; 2014 Oct; 16(10):845-60. PubMed ID: 25379021
[TBL] [Abstract][Full Text] [Related]
10. Extracellular vesicle-encapsulated microRNA-761 enhances pazopanib resistance in synovial sarcoma.
Shiozawa K; Shuting J; Yoshioka Y; Ochiya T; Kondo T
Biochem Biophys Res Commun; 2018 Jan; 495(1):1322-1327. PubMed ID: 29191657
[TBL] [Abstract][Full Text] [Related]
11. DUSP6 (MKP3) null mice show enhanced ERK1/2 phosphorylation at baseline and increased myocyte proliferation in the heart affecting disease susceptibility.
Maillet M; Purcell NH; Sargent MA; York AJ; Bueno OF; Molkentin JD
J Biol Chem; 2008 Nov; 283(45):31246-55. PubMed ID: 18753132
[TBL] [Abstract][Full Text] [Related]
12. Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo.
Tao Z; Le Blanc JM; Wang C; Zhan T; Zhuang H; Wang P; Yuan Z; Lu B
Clin Cancer Res; 2016 Jan; 22(1):122-33. PubMed ID: 26728409
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212.
Jing J; Greshock J; Holbrook JD; Gilmartin A; Zhang X; McNeil E; Conway T; Moy C; Laquerre S; Bachman K; Wooster R; Degenhardt Y
Mol Cancer Ther; 2012 Mar; 11(3):720-9. PubMed ID: 22169769
[TBL] [Abstract][Full Text] [Related]
14. Functional and therapeutic relevance of hepatocyte growth factor/c-MET signaling in synovial sarcoma.
Imura Y; Nakai T; Yamada S; Outani H; Takenaka S; Hamada K; Araki N; Itoh K; Yoshikawa H; Naka N
Cancer Sci; 2016 Dec; 107(12):1867-1876. PubMed ID: 27779808
[TBL] [Abstract][Full Text] [Related]
15. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
16. Dual-specificity phosphatase 6 (Dusp6), a negative regulator of FGF2/ERK1/2 signaling, enhances 17β-estradiol-induced cell growth in endometrial adenocarcinoma cell.
Zhang H; Guo Q; Wang C; Yan L; Fu Y; Fan M; Zhao X; Li M
Mol Cell Endocrinol; 2013 Aug; 376(1-2):60-9. PubMed ID: 23419500
[TBL] [Abstract][Full Text] [Related]
17. Development and characterization of a differentiated thyroid cancer cell line resistant to VEGFR-targeted kinase inhibitors.
Isham CR; Netzel BC; Bossou AR; Milosevic D; Cradic KW; Grebe SK; Bible KC
J Clin Endocrinol Metab; 2014 Jun; 99(6):E936-43. PubMed ID: 24628546
[TBL] [Abstract][Full Text] [Related]
18. Negative-feedback regulation of FGF signalling by DUSP6/MKP-3 is driven by ERK1/2 and mediated by Ets factor binding to a conserved site within the DUSP6/MKP-3 gene promoter.
Ekerot M; Stavridis MP; Delavaine L; Mitchell MP; Staples C; Owens DM; Keenan ID; Dickinson RJ; Storey KG; Keyse SM
Biochem J; 2008 Jun; 412(2):287-98. PubMed ID: 18321244
[TBL] [Abstract][Full Text] [Related]
19. Pazopanib-induced changes in protein expression signatures of extracellular vesicles in synovial sarcoma.
Shiozawa K; Yoshioka Y; Qiao Z; Shuting J; Ochiya T; Kondo T
Biochem Biophys Res Commun; 2018 Nov; 506(3):723-730. PubMed ID: 30454707
[TBL] [Abstract][Full Text] [Related]
20. Dual-specificity phosphatase 6 plays a critical role in the maintenance of a cancer stem-like cell phenotype in human endometrial cancer.
Kato M; Onoyama I; Yoshida S; Cui L; Kawamura K; Kodama K; Hori E; Matsumura Y; Yagi H; Asanoma K; Yahata H; Itakura A; Takeda S; Kato K
Int J Cancer; 2020 Oct; 147(7):1987-1999. PubMed ID: 32159851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
